Skip to content
HomeLatest newsWhat you need to know about Johnson & Johnson’s 2023 fourth-quarter and full-year earnings report
A collage of research scientists and medical imaging

What you need to know about Johnson & Johnson’s 2023 fourth-quarter and full-year earnings report

Check out this infographic breakdown of the company’s fourth-quarter and annual performance, with highlights from its Innovative Medicine and MedTech businesses.

This morning, Johnson & Johnson shared its 2023 fourth-quarter and full-year earnings report.

Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with approximately 130,000 employees across the globe working every day to help change the trajectory of health for humanity.

“Johnson & Johnson delivered strong results in 2023 while we continued to invest in advancing and strengthening our pipeline,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “Our diverse portfolio offers innovative solutions from both our Innovative Medicine and MedTech businesses and, coupled with a multifaceted approach to capital allocation, provides the foundation for us to further improve health outcomes for patients and deliver significant value to shareholders.”

For more details about the company’s 2023 fourth-quarter and full-year results, and to read a message from Chairman and Chief Executive Officer Joaquin Duato, here’s an infographic highlighting key stats.


2023 earnings infographic

Johnson & Johnson’s 2023 Earnings

Read the earnings press release, which includes fourth-quarter and full-year financial data for 2023.

Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.